ORNBV Orion Oyj Class B

Orion Corporation: Managers’ transactions – Hilpi Rautelin

Orion Corporation: Managers’ transactions – Hilpi Rautelin

ORION CORPORATION

MANAGERS’ TRANSACTIONS

30 AUGUST 2023 at 15.30 EEST              

        

Orion Corporation: Managers’ transactions – Hilpi Rautelin

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Hilpi Rautelin

Position: Member of the Board/Deputy member

Issuer: Orion Oyj

LEI: 74370029VAHCXDR7B745

Notification type: INITIAL NOTIFICATION

Reference number: 37188/7/8

____________________________________________

Transaction date: 2023-08-28

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009014369

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 27 Unit price: 35.85 EUR

(2): Volume: 28 Unit price: 36 EUR

(3): Volume: 26 Unit price: 36.1 EUR

(4): Volume: 26 Unit price: 36.05 EUR

(5): Volume: 41 Unit price: 36.1 EUR

(6): Volume: 33 Unit price: 35.95 EUR

(7): Volume: 200 Unit price: 35.95 EUR

(8): Volume: 200 Unit price: 35.95 EUR

(9): Volume: 52 Unit price: 35.85 EUR

(10): Volume: 200 Unit price: 35.85 EUR

(11): Volume: 220 Unit price: 35.9 EUR

(12): Volume: 200 Unit price: 35.9 EUR

Aggregated transactions (12):

Volume: 1253 Volume weighted average price: 35.92219 EUR

____________________________________________

Transaction date: 2023-08-28

Venue: CEUD

Instrument type: SHARE

ISIN: FI0009014369

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 75 Unit price: 35.92 EUR

Aggregated transactions (1):

Volume: 75 Volume weighted average price: 35.92 EUR

____________________________________________

Transaction date: 2023-08-28

Venue: CEUX

Instrument type: SHARE

ISIN: FI0009014369

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 130 Unit price: 35.95 EUR

(2): Volume: 140 Unit price: 35.85 EUR

Aggregated transactions (2):

Volume: 270 Volume weighted average price: 35.89815 EUR

____________________________________________

Transaction date: 2023-08-28

Venue: TQEX

Instrument type: SHARE

ISIN: FI0009014369

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 40 Unit price: 35.95 EUR

Aggregated transactions (1):

Volume: 40 Volume weighted average price: 35.95 EUR

____________________________________________

Transaction date: 2023-08-29

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009014369

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 273 Unit price: 37 EUR

(2): Volume: 90 Unit price: 37 EUR

(3): Volume: 170 Unit price: 37 EUR

(4): Volume: 198 Unit price: 36.95 EUR

(5): Volume: 26 Unit price: 36.65 EUR

(6): Volume: 26 Unit price: 36.7 EUR

(7): Volume: 58 Unit price: 36.7 EUR

(8): Volume: 28 Unit price: 36.65 EUR

(9): Volume: 27 Unit price: 36.6 EUR

(10): Volume: 26 Unit price: 36.55 EUR

(11): Volume: 26 Unit price: 36.55 EUR

(12): Volume: 40 Unit price: 36.5 EUR

(13): Volume: 26 Unit price: 35.95 EUR

Aggregated transactions (13):

Volume: 1014 Volume weighted average price: 36.86637 EUR

____________________________________________

Transaction date: 2023-08-29

Venue: TQEM

Instrument type: SHARE

ISIN: FI0009014369

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 23 Unit price: 36.78 EUR

(2): Volume: 24 Unit price: 36.75 EUR

(3): Volume: 25 Unit price: 36.75 EUR

(4): Volume: 25 Unit price: 36.7 EUR

Aggregated transactions (4):

Volume: 97 Volume weighted average price: 36.74423 EUR

____________________________________________

Transaction date: 2023-08-29

Venue: CEUX

Instrument type: SHARE

ISIN: FI0009014369

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 181 Unit price: 36.95 EUR

(2): Volume: 30 Unit price: 36.95 EUR

(3): Volume: 40 Unit price: 36.95 EUR

Aggregated transactions (3):

Volume: 251 Volume weighted average price: 36.95 EUR

Orion Corporation

Liisa Hurme



President and CEO
   Olli Huotari



SVP, Corporate Functions
 

                                                

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland



Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.



EN
30/08/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orion Oyj Class B

 PRESS RELEASE

Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal...

Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal  ORION CORPORATION PRESS RELEASE 30 SEPTEMBER 2025 at 13.00 EEST         Orion’s phase 2 study of ODM-105 in insomnia did not meet primary goal  Orion to discontinue development of ODM-105 for insomnia.ODM-105 (tasipimidine) was well tolerated. Detailed results, including safety data, and their assessment are to be finalized. Orion Corporation today announced that its candidate ODM-105 (tasipimidine) did not meet the primary goal in the clinical Phase 2 UNITAS study for the treatment of patients with insomnia. Accor...

 PRESS RELEASE

Orionin vaiheen 2 tutkimus ODM-105:llä unettomuuden hoidossa ei saavut...

Orionin vaiheen 2 tutkimus ODM-105:llä unettomuuden hoidossa ei saavuttanut ensisijaista tavoitettaan ORION OYJ        LEHDISTÖTIEDOTE        30.9.2025 KLO 13.00         Orionin vaiheen 2 tutkimus ODM-105:llä unettomuuden hoidossa ei saavuttanut ensisijaista tavoitettaan Orion lopettaa ODM-105:n kehityksen unettomuuden hoitoon.ODM-105 (tasipimidiini) oli hyvin siedetty. Yksityiskohtaisten tulosten, mukaan lukien turvallisuusdata, valmistuminen ja arviointi on vielä kesken. Orion Oyj:n lääkekandidaatti ODM-105 (tasipimidiini) ei saavuttanut ensisijaista tavoitettaan unettomuuspotilaiden h...

 PRESS RELEASE

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securi...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS30 September 2025 at 9.00 EEST          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 26 Septembe...

 PRESS RELEASE

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoit...

Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) ORION OYJ        PÖRSSITIEDOTE / SUURIMMAT OSAKKEENOMISTAJAT -TIEDOTE        30.9.2025 KLO 9.00         Orion Oyj: Arvopaperimarkkinalain 9. luvun 10. pykälän mukainen ilmoitus (BlackRock, Inc.) Orion Oyj on saanut Arvopaperimarkkinalain 9. luvun 5 §:n mukaisen ilmoituksen, jonka mukaan BlackRock, Inc.:n ja sen rahastojen suoraan, välillisesti ja rahoitusinstrumenttien kautta omistamien Orionin osakkeiden osuus on 26.9.2025 alittanut viisi (5) prosenttia Orion Oyj:n kaikista osakkeista. BlackRoc...

 PRESS RELEASE

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securi...

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS26 September 2025 at 16.30 EEST          Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 25 Septemb...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch